FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a monoclonal antibody or its antigen-binding fragment that have selective binding with TRA-podokalixin. An antitumor therapeutic agent is also disclosed for the treatment of malignant neoplasm related to TRA-podokalixin, containing a monoclonal antibody or its antigen-binding fragment.
EFFECT: invention has a capability of effective treatment of diseases associated with TRA-podokalixin.
9 cl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF O-ACETYLATED GD2 GANGLIOSIDE AS TARGET AS NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACH IN MALIGNANT GROWTHS CONTAINING TUMOUR STEM CELLS | 2014 |
|
RU2702428C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2624049C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2595400C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2012 |
|
RU2611197C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2610428C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING MALIGNANT GROWTHS | 2009 |
|
RU2498819C2 |
| ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | 2012 |
|
RU2676731C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
